Systemic inflammatory markers in ageing, Alzheimer's disease and other dementias.

IF 10.6 1区医学 Q1 CLINICAL NEUROLOGY

Brain Pub Date : 2025-02-03 DOI:10.1093/brain/awae230

Huimin Cai, Tan Zhao, Yana Pang, Xiaofeng Fu, Ziye Ren, Shuiyue Quan, Longfei Jia

{"title":"Systemic inflammatory markers in ageing, Alzheimer's disease and other dementias.","authors":"Huimin Cai, Tan Zhao, Yana Pang, Xiaofeng Fu, Ziye Ren, Shuiyue Quan, Longfei Jia","doi":"10.1093/brain/awae230","DOIUrl":null,"url":null,"abstract":"<p><p>Systemic inflammation with alterations in inflammatory markers is involved in ageing and Alzheimer's disease. However, few studies have investigated the longitudinal trajectories of systemic inflammatory markers during ageing and Alzheimer's disease, and specific markers contributing to Alzheimer's disease remain undetermined. In this study, a longitudinal cohort (cohort 1: n = 290; controls, 136; preclinical Alzheimer's disease, 154) and a cross-sectional cohort (cohort 2: n = 351; controls, 62; Alzheimer's disease, 63; vascular dementia, 58; Parkinson's disease dementia, 56; behavioural variant frontotemporal dementia, 57; dementia with Lewy bodies, 55) were included. Plasma levels of inflammatory markers were measured every 2 years during a 10-year follow-up in the longitudinal cohort and once in the cross-sectional cohort. The study demonstrated that the inflammatory markers significantly altered during both ageing and the development of Alzheimer's disease. However, only complement C3, interleukin-1β and interleukin-6 exhibited significant changes in participants with preclinical Alzheimer's disease, and their longitudinal changes were significantly associated with the development of Alzheimer's disease compared to controls over the 10-year follow-up. In the cross-sectional cohort, complement C3 demonstrated specificity to Alzheimer's disease, while interleukin-1β and interleukin-6 were also altered in other dementias. The study provides a new perspective on the involvement of inflammatory markers in the ageing process and the development of Alzheimer's disease, implying that regulating inflammation may have a pivotal role in promoting successful ageing and in the prevention and treatment of Alzheimer's disease.</p>","PeriodicalId":9063,"journal":{"name":"Brain","volume":" ","pages":"480-492"},"PeriodicalIF":10.6000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/brain/awae230","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Systemic inflammation with alterations in inflammatory markers is involved in ageing and Alzheimer's disease. However, few studies have investigated the longitudinal trajectories of systemic inflammatory markers during ageing and Alzheimer's disease, and specific markers contributing to Alzheimer's disease remain undetermined. In this study, a longitudinal cohort (cohort 1: n = 290; controls, 136; preclinical Alzheimer's disease, 154) and a cross-sectional cohort (cohort 2: n = 351; controls, 62; Alzheimer's disease, 63; vascular dementia, 58; Parkinson's disease dementia, 56; behavioural variant frontotemporal dementia, 57; dementia with Lewy bodies, 55) were included. Plasma levels of inflammatory markers were measured every 2 years during a 10-year follow-up in the longitudinal cohort and once in the cross-sectional cohort. The study demonstrated that the inflammatory markers significantly altered during both ageing and the development of Alzheimer's disease. However, only complement C3, interleukin-1β and interleukin-6 exhibited significant changes in participants with preclinical Alzheimer's disease, and their longitudinal changes were significantly associated with the development of Alzheimer's disease compared to controls over the 10-year follow-up. In the cross-sectional cohort, complement C3 demonstrated specificity to Alzheimer's disease, while interleukin-1β and interleukin-6 were also altered in other dementias. The study provides a new perspective on the involvement of inflammatory markers in the ageing process and the development of Alzheimer's disease, implying that regulating inflammation may have a pivotal role in promoting successful ageing and in the prevention and treatment of Alzheimer's disease.

查看原文本刊更多论文

老龄化、阿尔茨海默病和其他痴呆症中的全身炎症标志物。

全身炎症与炎症标志物的变化与衰老和阿尔茨海默病有关。然而，很少有研究对衰老和阿尔茨海默病期间全身炎症标志物的纵向轨迹进行调查，而且导致阿尔茨海默病的特定标志物仍未确定。本研究纳入了一个纵向队列（队列 1：n = 290；对照组，136；临床前阿尔茨海默病，154）和一个横向队列（队列 2：n = 351；对照组，62；阿尔茨海默病，63；血管性痴呆，58；帕金森病痴呆，56；行为变异型额颞叶痴呆，57；路易体痴呆，55）。在为期 10 年的随访中，纵向队列每两年测量一次血浆中的炎症标志物水平，横向队列则每两年测量一次血浆中的炎症标志物水平。研究表明，炎症标志物在衰老和阿尔茨海默病的发展过程中都发生了显著变化。然而，与对照组相比，只有补体C3、白细胞介素-1β和白细胞介素-6在临床前阿尔茨海默氏症患者中出现了显著变化，而且在10年的随访中，它们的纵向变化与阿尔茨海默氏症的发展显著相关。在横断面队列中，补体C3显示出对阿尔茨海默病的特异性，而白细胞介素-1β和白细胞介素-6在其他痴呆症中也发生了变化。这项研究为炎症标志物参与衰老过程和阿尔茨海默病的发展提供了一个新的视角，意味着调节炎症可能在促进成功衰老以及预防和治疗阿尔茨海默病方面发挥关键作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Brain 医学-临床神经学

CiteScore

20.30

自引率

4.10%

发文量

458

审稿时长

3-6 weeks

期刊介绍： Brain, a journal focused on clinical neurology and translational neuroscience, has been publishing landmark papers since 1878. The journal aims to expand its scope by including studies that shed light on disease mechanisms and conducting innovative clinical trials for brain disorders. With a wide range of topics covered, the Editorial Board represents the international readership and diverse coverage of the journal. Accepted articles are promptly posted online, typically within a few weeks of acceptance. As of 2022, Brain holds an impressive impact factor of 14.5, according to the Journal Citation Reports.